Ac immune and takeda sign exclusive option and license agreement for active immunotherapy targeting amyloid beta for alzheimer's disease

Osaka, japan & cambridge, mass & lausanne, switzerland--(business wire)--takeda (tse:4502/nyse:tak) and ac immune sa (nasdaq: aciu) today announced an exclusive, worldwide option and license agreement for ac immune's active immunotherapies targeting toxic forms of amyloid beta (abeta), including aci-24.060 for the treatment of alzheimer's disease. aci-24.060 is an anti-abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of abeta believed to.
ACIU Ratings Summary
ACIU Quant Ranking